Prostate Cancer Microparticles Expressing CD151 as a Predictive Biomarker for Progression to Metastasis
Final rept. 1 Sep-31 Nov 2012
UNIVERSITY OF WESTERN ONTARIO LONDON HEALTH SCIENCES CENTER
Pagination or Media Count:
We have found that the monoclonal antibody specific for a specific epitope of CD151 that is hypothesized to be expressed on prostate cancer microparticles from metastatic prostate cancer patients is also expressed on a subpopulation of prostate cancer microparticles from localized prostate cancer patients undergoing radical treatment. Therefore, a new direction is to analyze prostate cancer microparticles from patients on active surveillance low risk PCa patients under watchful waiting and we hypothesize that these patients will have the lowest percentage of 1A5-positive prostate microparticles. Those patients that do have high levels of 1A5-positive prostate microparticles will be followed to determine if their disease progresses and requires radical therapy surgery, radiation.
- Medicine and Medical Research